Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients.

Rosenbaum BE, Schafer CN, Han SW, Osman I, Zhong H, Brinster N.

Mod Pathol. 2017 Oct;30(10):1402-1410. doi: 10.1038/modpathol.2017.64. Epub 2017 Jul 21.

PMID:
28731044
2.

A Qualitative Study of Quality of Life Concerns following a Melanoma Diagnosis.

Vogel RI, Strayer LG, Ahmed RL, Blaes A, Lazovich D.

J Skin Cancer. 2017;2017:2041872. doi: 10.1155/2017/2041872. Epub 2017 May 28.

3.

Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy.

Rubinstein JC, Han G, Jackson L, Bulloch K, Ariyan S, Narayan D, Rothberg BG, Han D.

Cancer Med. 2016 Oct;5(10):2832-2840. doi: 10.1002/cam4.922. Epub 2016 Sep 27.

4.

Update and Review on the Surgical Management of Primary Cutaneous Melanoma.

Leilabadi SN, Chen A, Tsai S, Soundararajan V, Silberman H, Wong AK.

Healthcare (Basel). 2014 Jun 10;2(2):234-49. doi: 10.3390/healthcare2020234. Review.

5.

Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Gimotty PA, Shore R, Lozon NL, Whitlock J, He S, Vigneau FD, Dickie L, Elder DE, Xu X, Schwartz AG, Guerry D.

J Invest Dermatol. 2016 Nov;136(11):2168-2172. doi: 10.1016/j.jid.2016.05.121. Epub 2016 Jun 25.

6.

Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.

Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D.

PLoS One. 2016 May 23;11(5):e0156115. doi: 10.1371/journal.pone.0156115. eCollection 2016.

7.

Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.

Zhang G, Cheng Y, Chen G, Tang Y, Ardekani G, Rotte A, Martinka M, McElwee K, Xu X, Wang Q, Zhou Y.

Oncotarget. 2015 Sep 8;6(26):23026-35.

8.

Survival rates of patients with metastatic malignant melanoma.

Sandru A, Voinea S, Panaitescu E, Blidaru A.

J Med Life. 2014 Oct-Dec;7(4):572-6.

9.

In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, Lloyd MC, Enkemann SA, Smalley KS, Sondak VK, Vagner J, Morse DL.

Mol Pharm. 2013 Aug 5;10(8):3175-85. doi: 10.1021/mp400222j. Epub 2013 Jul 8.

10.

The analysis of reasons for malignant skin tumors late diagnosis.

Karabeg R, Lukic D, Janjic Z, Jakirlic M, Dujso V, Bandic J, Babic N, Karabeg A, Guzvic V, Lazic P.

Mater Sociomed. 2012;24(2):73-5. doi: 10.5455/msm.2012.24.73-75.

11.

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

El Hajj P, Journe F, Wiedig M, Laios I, Salès F, Galibert MD, Van Kempen LC, Spatz A, Badran B, Larsimont D, Awada A, Ghanem G.

Br J Cancer. 2013 Apr 30;108(8):1641-7. doi: 10.1038/bjc.2013.115. Epub 2013 Mar 21.

12.

Nonlinear microscopy of eumelanin and pheomelanin with subcellular resolution.

Simpson MJ, Wilson JW, Phipps MA, Robles FE, Selim MA, Warren WS.

J Invest Dermatol. 2013 Jul;133(7):1822-6. doi: 10.1038/jid.2013.37. Epub 2013 Jan 25.

13.

Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Tafreshi NK, Huang X, Moberg VE, Barkey NM, Sondak VK, Tian H, Morse DL, Vagner J.

Bioconjug Chem. 2012 Dec 19;23(12):2451-9. doi: 10.1021/bc300549s. Epub 2012 Nov 27.

14.

Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.

Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Cruse CW, Sarnaik AA, Puleo C, Sondak VK, Zager JS.

Ann Surg Oncol. 2012 Oct;19(11):3335-42. doi: 10.1245/s10434-012-2469-1. Epub 2012 Jul 6.

15.

Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

McClain SE, Shada AL, Barry M, Patterson JW, Slingluff CL Jr.

Melanoma Res. 2012 Aug;22(4):302-9. doi: 10.1097/CMR.0b013e328353e673.

16.

Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?

Göppner D, Leverkus M.

J Skin Cancer. 2011;2011:521947. doi: 10.1155/2011/521947. Epub 2011 Oct 11.

17.

Increased shedding of HU177 correlates with worse prognosis in primary melanoma.

Hamilton HK, Rose AE, Christos PJ, Shapiro RL, Berman RS, Mazumdar M, Ma MW, Krich D, Liebes L, Brooks PC, Osman I.

J Transl Med. 2010 Feb 23;8:19. doi: 10.1186/1479-5876-8-19.

18.

Predictors of occult nodal metastasis in patients with thin melanoma.

Faries MB, Wanek LA, Elashoff D, Wright BE, Morton DL.

Arch Surg. 2010 Feb;145(2):137-42. doi: 10.1001/archsurg.2009.271.

19.

Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).

Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, Polsky D, Mazumdar M, Osman I.

Cancer. 2009 Feb 15;115(4):869-79. doi: 10.1002/cncr.24044.

20.

Importance of sentinel lymph node biopsy in patients with thin melanoma.

Wright BE, Scheri RP, Ye X, Faries MB, Turner RR, Essner R, Morton DL.

Arch Surg. 2008 Sep;143(9):892-9; discussion 899-900. doi: 10.1001/archsurg.143.9.892.

Supplemental Content

Support Center